The study’s small size limits interpretation, but it remains the largest real-world data available, experts said.

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...

Recent advances in molecular and pathobiology have brought the field of dermatology to the cusp of reaching a goal that ...

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

CatalYm today announced the presentation of the first preclinical data demonstrating that the company's clinical-stage antibody visugromab can improve the anti-tumor activity of antibody-drug ...

Italfarmaco S.p.A., Cinisello Balsamo, Italy.

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

MediLink Therapeutics (Suzhou) Co., Ltd., Suzhou, China.

Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification ...

Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago ...